LUNG
What one share of Pulmonx holds
Surgical and Medical Instruments and Apparatus
We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”).
Pulmonx’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.10 |
|---|---|
| Profit | −$1.15 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.74 |
| Cash and investments | $1.30 |
| Debt | $0.87 |
| Book value | $0.91 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $11.94 | −$11.03 | $0.19 | −$11.17 | — | −$99.91 |
| 2019 | $18.35 | −$11.66 | $0.41 | −$12.10 | — | −$89.22 |
| 2020 | $3.21 | −$3.16 | $0.09 | −$3.10 | — | — |
| 2021 | $1.34 | −$1.35 | $0.10 | −$1.25 | — | $5.23 |
| 2022 | $1.45 | −$1.59 | $0.04 | −$1.25 | — | $4.10 |
| 2023 | $1.81 | −$1.60 | $0.02 | −$1.01 | — | $3.07 |
| 2024 | $2.14 | −$1.44 | $0.04 | −$0.84 | — | $2.16 |
| 2025 | $2.22 | −$1.33 | $0.01 | −$0.81 | — | $1.30 |